NDC 44567-820-01 - ertapenem
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 44567-820
- Requested NDC
- 44567-820-01
- Package NDCs from labels
- 44567-820-01, 44567-820-10
- Manufacturer
- WG Critical Care, LLC | ACS Dobfar SpA
- Effective date
- 2022-08-31
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| ertapenem - WG Critical Care, LLC | ACS Dobfar SpA | WG Critical Care, LLC | ACS Dobfar SpA | 2022-08-31 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 44567-820-01 | ertapenem | 1 in 1 VIAL, SINGLE-DOSE | INJECTION, POWDER, LYOPHILIZED, | 1 | 7 | |
| 44567-820-10 | ertapenem | 10 in 1 CARTON | INJECTION, POWDER, LYOPHILIZED, | 10 | 7 |
DailyMed Dashboard NDC Coverage#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Sodium Bicarbonate | SODIUM BICARBONATE | Medical Purchasing Solutions, LLC | 09cf38c2-0b44-eca1-e063-6294a90a72d8 | 2023-11-10 | Warnings, Adverse reactions | 8MDF5V39QO |
| omeprazole sodium bicarbonate | OMEPRAZOLE SODIUM BICARBONATE | Cipla USA Inc. | 9cdde58a-ae8a-451f-92cf-cab178e4ba92 | 2023-11-01 | Warnings, Adverse reactions | 8MDF5V39QO |
| Sodium Bicarbonate | SODIUM BICARBONATE | APNAR PHARMA LP | e206c240-55c2-2d00-e053-2a95a90a1779 | 2023-10-21 | Boxed warning, Warnings | 8MDF5V39QO |
| Omeprazole/Sodium Bicarbonate | OMEPRAZOLE | Strides Pharma Science Limited | cf6d293e-d70d-443e-8292-d693e93aab55 | 2023-09-21 | Warnings, Adverse reactions | 8MDF5V39QO |
| Sodium Bicarbonate | SODIUM BICARBONATE | OMNIVIUM PHARMACEUTICALS LLC. | aea54f8d-1cdd-4a5c-a2f7-7317ae4c8fbc | 2023-08-10 | Warnings, Adverse reactions | 8MDF5V39QO |
| Omeprazole and Sodium Bicarbonate | OMEPRAZOLE AND SODIUM BICARBONATE | Dr. Reddy's Laboratories Inc., | c6b5f808-4a49-1303-9711-badb022ecd70 | 2023-07-19 | Warnings | 8MDF5V39QO |
| Sodium Bicarbonate | SODIUM BICARBONATE | A-S Medication Solutions | 619cb558-84e5-43ea-91e9-28c764f9f9c0 | 2023-06-21 | Warnings, Adverse reactions | 8MDF5V39QO |
| PEG-3350 and Electrolytes | POLYETHYLENE GLYCOL 3350, SODIUM SULFATE ANHYDROUS, SODIUM BICARBONATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE | A-S Medication Solutions | 7a2d8dab-750f-43c1-933c-4169a840c60c | 2023-06-20 | Warnings, Adverse reactions | 8MDF5V39QO |
| Sodium Bicarbonate | SODIUM BICARBONATE | Medical Purchasing Solutions, LLC | b620938d-ab2d-0934-e053-2a95a90a8483 | 2023-05-23 | Warnings, Adverse reactions | 8MDF5V39QO |
| Sodium Bicarbonate | SODIUM BICARBONATE | Medical Purchasing Solutions, LLC | d1636b56-ad83-4439-e053-2a95a90a135e | 2023-05-02 | Warnings, Adverse reactions | 8MDF5V39QO |
| POLYETHYLENE GLYCOL-3350 AND ELECTROLYTES | POLYETHYLENE GLYCOL-3350 AND ELECTROLYTES | Novel Laboratories, Inc. | 29d821ff-389c-41fb-8a27-89bd3f022b82 | 2023-02-08 | Warnings, Adverse reactions | 8MDF5V39QO |
| Omeprazole, Sodium bicarbonate | OMEPRAZOLE, SODIUM BICARBONATE | Guardian Drug Company | e5c6c2cf-fb3b-456a-a0a0-be396d6f8319 | 2022-11-08 | Warnings, Adverse reactions | 8MDF5V39QO |
| Ertapenem | ERTAPENEM SODIUM | Fresenius Kabi USA, LLC | 666c9f33-ea9e-4667-b8bd-f8b1b6b6be51 | 2022-11-08 | Warnings, Adverse reactions | ANDA208790 1734683 2T90KE67L0 |
| ertapenem | ERTAPENEM | WG Critical Care, LLC | cf3cfa6b-211c-452b-b18b-e462b21e6909 | 2022-08-31 | Warnings, Adverse reactions | ANDA208790 44567-820-10 44567-820-01 44567-820 44567082001 1734683 befbf704-5aae-474b-8457-c77b2ab7835e cf3cfa6b-211c-452b-b18b-e462b21e6909 2T90KE67L0 |
| Ertapenem | ERTAPENEM SODIUM | Gland Pharma Limited | f74cca2f-e775-4580-acae-3a0c47dd24d9 | 2022-04-12 | Warnings, Adverse reactions | 1734683 2T90KE67L0 |
| Sodium Bicarbonate | SODIUM BICARBONATE | International Medication Systems, Limited | 77698221-a01d-4568-a7bc-d3d4e982875d | 2021-12-15 | Warnings, Adverse reactions | 8MDF5V39QO |
| 8.4% SODIUM BICARBONATE | 8.4% SODIUM BICARBONATE | HF Acquisition Co. LLC, DBA HealthFirst | 74d8bb7a-9e7a-105f-e053-2a91aa0aec92 | 2021-05-03 | Warnings, Adverse reactions | 8MDF5V39QO |
| ERTAPENEM SODIUM | ERTAPENEM | Dr.Reddys Laboratories Inc., | 32d9f095-ca39-7e22-6264-b54f2daaee57 | 2021-04-30 | Warnings, Adverse reactions | 1734683 2T90KE67L0 |
| SODIUM BICARBONATE | SODIUM BICARBONATE | Medical Purchasing Solutions, LLC | bfc9c321-665c-ca97-e053-2995a90a7954 | 2021-04-12 | Warnings, Adverse reactions | 8MDF5V39QO |
| Good Sense Omeprazole and Sodium Bicarbonate | OMEPRAZOLE, SODIUM BICARBONATE | L. Perrigo Company | bcf32242-de17-4da1-b707-4ce26262eb78 | 2020-11-16 | Warnings | 8MDF5V39QO |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.